{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:34Z","timestamp":1772120014246,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T00:00:00Z","timestamp":1529971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI110503"],"award-info":[{"award-number":["AI110503"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11926-018-0754-0","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T03:32:44Z","timestamp":1529983964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention"],"prefix":"10.1007","volume":"20","author":[{"given":"Kevin D.","family":"Deane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,26]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","volume":"71","author":"DM Gerlag","year":"2012","unstructured":"Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the study group for risk factors for rheumatoid arthritis. Ann Rheum Dis. 2012;71:638\u201341.","journal-title":"Ann Rheum Dis"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/art.1780311004","volume":"31","author":"A del Puente","year":"1988","unstructured":"del Puente A, Knowler WC, Pettitt DJ, Bennett PH. The incidence of rheumatoid arthritis is predicted by rheumatoid factor titer in a longitudinal population study. Arthritis Rheum. 1988;31:1239\u201344.","journal-title":"Arthritis Rheum"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.56.6.351","volume":"56","author":"K Aho","year":"1997","unstructured":"Aho K, Heliovaara M, Knekt P, Reunanen A, Aromaa A, Leino A, et al. Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis. 1997;56:351\u20136.","journal-title":"Ann Rheum Dis"},{"key":"754_CR4","first-page":"1282","volume":"18","author":"K Aho","year":"1991","unstructured":"Aho K, Heliovaara M, Maatela J, Tuomi T, Palosuo T. Rheumatoid factors antedating clinical rheumatoid arthritis. J Rheumatol. 1991;18:1282\u20134.","journal-title":"J Rheumatol"},{"key":"754_CR5","first-page":"2743","volume":"27","author":"K Aho","year":"2000","unstructured":"Aho K, Palosuo T, Heliovaara M, Knekt P, Alha P, von Essen R. Antifilaggrin antibodies within \"normal\" range predict rheumatoid arthritis in a linear fashion. J Rheumatol. 2000;27:2743\u20136.","journal-title":"J Rheumatol"},{"key":"754_CR6","first-page":"1278","volume":"20","author":"K Aho","year":"1993","unstructured":"Aho K, von Essen R, Kurki P, Palosuo T, Heliovaara M. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol. 1993;20:1278\u201381.","journal-title":"J Rheumatol"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/rheumatology\/31.6.365","volume":"31","author":"AJ Silman","year":"1992","unstructured":"Silman AJ, Hennessy E, Ollier B. Incidence of rheumatoid arthritis in a genetically predisposed population. Br J Rheumatol. 1992;31:365\u20138.","journal-title":"Br J Rheumatol"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","unstructured":"Rantapaa-Dahlqvist S, de Jong BA, Berglin E, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741\u20139.","journal-title":"Arthritis Rheum"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"MM Nielen","year":"2004","unstructured":"Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380\u20136.","journal-title":"Arthritis Rheum"},{"key":"754_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/ard.2007.076679","volume":"67","author":"DS Majka","year":"2008","unstructured":"Majka DS, Deane KD, Parrish LA, Lazar AA, Baron AE, Walker CW, et al. Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis. 2008;67:801\u20137.","journal-title":"Ann Rheum Dis"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3899\/jrheum.080895","volume":"36","author":"LB Chibnik","year":"2009","unstructured":"Chibnik LB, Mandl LA, Costenbader KH, Schur PH, Karlson EW. Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis. J Rheumatol. 2009;36:706\u201311.","journal-title":"J Rheumatol"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/ard.2008.105759","volume":"69","author":"WH Bos","year":"2010","unstructured":"Bos WH, Wolbink GJ, Boers M, Tijhuis GJ, de Vries N, van der Horst-Bruinsma IE, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69:490\u20134.","journal-title":"Ann Rheum Dis"},{"key":"754_CR13","doi-asserted-by":"crossref","unstructured":"van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2012.","DOI":"10.1136\/annrheumdis-2012-202127"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1136\/annrheumdis-2012-202254","volume":"72","author":"MJ de Hair","year":"2013","unstructured":"\u2022 de Hair MJ, Landewe RB, van de Sande MG, et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis. 2013;72:1654\u20138. This citations represent prospective studies of ACPA individuals, many of whom progress to clinically-apparent IA\/RA. These provide basis for high positive predictive values of ACPA, RF and other factors for RA that underpin the development of clinical prevention trials.","journal-title":"Ann Rheum Dis"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/art.39297","volume":"67","author":"C Ramos-Remus","year":"2015","unstructured":"\u2022\u2022 Ramos-Remus C, Castillo-Ortiz JD, Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, Vargas-Serafin CO, et al. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis Rheumatol. 2015;67:2837\u201344. This citations represent prospective studies of ACPA individuals, many of whom progress to clinically-apparent IA\/RA. These provide basis for high positive predictive values of ACPA, RF and other factors for RA that underpin the development of clinical prevention trials.","journal-title":"Arthritis Rheumatol"},{"key":"754_CR16","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1136\/annrheumdis-2014-205227","volume":"74","author":"C Rakieh","year":"2015","unstructured":"\u2022\u2022 Rakieh C, Nam JL, Hunt L, Hensor EMA, Das S, Bissell LA, et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis. 2015;74:1659\u201366. This citations represent prospective studies of ACPA individuals, many of whom progress to clinically-apparent IA\/RA. These provide basis for high positive predictive values of ACPA, RF and other factors for RA that underpin the development of clinical prevention trials.","journal-title":"Ann Rheum Dis"},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1093\/rheumatology\/kex360","volume":"56","author":"RW Gan","year":"2017","unstructured":"\u2022 Gan RW, Bemis EA, Demoruelle MK, Striebich CC, Brake S, Feser ML, et al. The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population. Rheumatology (Oxford). 2017;56:2229\u201336. This citations represent prospective studies of ACPA individuals, many of whom progress to clinically-apparent IA\/RA. These provide basis for high positive predictive values of ACPA, RF and other factors for RA that underpin the development of clinical prevention trials.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11926-011-0193-7","volume":"13","author":"MK Demoruelle","year":"2011","unstructured":"Demoruelle MK, Deane K. Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance. Curr Rheumatol Rep. 2011;13:421\u201330.","journal-title":"Curr Rheumatol Rep"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/art.38017","volume":"65","author":"MK Demoruelle","year":"2013","unstructured":"Demoruelle MK, Parish MC, Derber LA, Kolfenbach JR, Hughes-Austin JM, Weisman MH, et al. Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 2013;65:2243\u201352.","journal-title":"Arthritis Rheum"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/ard.2010.132662","volume":"70","author":"LA van de Stadt","year":"2011","unstructured":"van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis. 2011;70:128\u201333.","journal-title":"Ann Rheum Dis"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"e35296","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7:e35296.","journal-title":"PLoS One"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1002\/art.27533","volume":"62","author":"A Ercan","year":"2010","unstructured":"Ercan A, Cui J, Chatterton DE, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62:2239\u201348.","journal-title":"Arthritis Rheum"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/annrheumdis-2016-209154","volume":"76","author":"RW Gan","year":"2017","unstructured":"Gan RW, Demoruelle MK, Deane KD, Weisman MH, Buckner JH, Gregersen PK, et al. Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis. Ann Rheum Dis. 2017;76:147\u201352.","journal-title":"Ann Rheum Dis"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","volume":"73","author":"J Shi","year":"2014","unstructured":"Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73:780\u20133.","journal-title":"Ann Rheum Dis"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1002\/art.27638","volume":"62","author":"KD Deane","year":"2010","unstructured":"Deane KD, O'Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010;62:3161\u201372.","journal-title":"Arthritis Rheum"},{"key":"754_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/art.27186","volume":"62","author":"H Kokkonen","year":"2010","unstructured":"Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62:383\u201391.","journal-title":"Arthritis Rheum"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2017.08.003","volume":"31","author":"KD Deane","year":"2017","unstructured":"Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017;31:3\u201318.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/BOR.0000000000000017","volume":"26","author":"MK Demoruelle","year":"2014","unstructured":"Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26:64\u201371.","journal-title":"Curr Opin Rheumatol"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1136\/annrheumdis-2012-202127","volume":"72","author":"LA van de Stadt","year":"2013","unstructured":"\u2022 van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis. 2013;72:1920\u20136. This citations represent prospective studies of ACPA individuals, many of whom progress to clinically-apparent IA\/RA. These provide basis for high positive predictive values of ACPA, RF and other factors for RA that underpin the development of clinical prevention trials.","journal-title":"Ann Rheum Dis"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1186\/ar3028","volume":"12","author":"LA van de Stadt","year":"2010","unstructured":"van de Stadt LA, Bos WH, Meursinge Reynders M, Wieringa H, Turkstra F, van der Laken CJ, et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther. 2010;12:R98.","journal-title":"Arthritis Res Ther"},{"key":"754_CR31","doi-asserted-by":"crossref","unstructured":"de Pablo P, Romaguera D, Fisk HL, et al. High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study. Ann Rheum Dis. 2018.","DOI":"10.1136\/annrheumdis-2017-212274"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/ard.2008.105767","volume":"69","author":"WH Bos","year":"2010","unstructured":"\u2022 Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. Ann Rheum Dis. 2010;69:571\u20134. This citations are descriptions of the completed or in-process prevention trials in RA. They are useful to review to understand the current understanding of trial design and intervention to prevent RA.","journal-title":"Ann Rheum Dis"},{"key":"754_CR33","unstructured":"\u2022 European League Against Rheumatism (EULAR) Congress 2016: abstract OP0182. Presented June 9, 2016. Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease (PRAIRI) http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=2442 . This citations are descriptions of the completed or in-process prevention trials in RA. They are useful to review to understand the current understanding of trial design and intervention to prevent RA."},{"key":"754_CR34","unstructured":"\u2022 Strategy for the prevention of onset of clinically-apparent rheumatoid arthritis (StopRA) ClinicalTrials.gov identifier NCT02603146. Cited 3-Mar-2018. at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603146 .) This citations are descriptions of the completed or in-process prevention trials in RA. They are useful to review to understand the current understanding of trial design and intervention to prevent RA."},{"key":"754_CR35","unstructured":"\u2022 Arthritis Prevention in the Pre-Clinical Phase of RA with Abatacept (APIPPRA) ISRCTN No. 46017566 Cited 3-Mar-2018. at http:\/\/www.isrctn.com\/ISRCTN46017566 .) This citations are descriptions of the completed or in-process prevention trials in RA. They are useful to review to understand the current understanding of trial design and intervention to prevent RA."},{"key":"754_CR36","unstructured":"\u2022 STAPRA (Statins for the Prevention of Rheumatoid Arthritis). Cited 21-Mar-2018. at http:\/\/www.trialregister.nl\/trialreg\/admin\/rctview.asp?TC=5265 .) This citations are descriptions of the completed or in-process prevention trials in RA. They are useful to review to understand the current understanding of trial design and intervention to prevent RA."},{"key":"754_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11926-016-0598-4","volume":"18","author":"A Finckh","year":"2016","unstructured":"Finckh A, Escher M, Liang MH, Bansback N. Preventive treatments for rheumatoid arthritis: issues regarding patient preferences. Curr Rheumatol Rep. 2016;18:51.","journal-title":"Curr Rheumatol Rep"},{"key":"754_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.25036","volume":"62","author":"O Snir","year":"2010","unstructured":"Snir O, Widhe M, Hermansson M, von Spee C, Lindberg J, Hensen S, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 2010;62:44\u201352.","journal-title":"Arthritis Rheum"},{"key":"754_CR39","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/art.30655","volume":"64","author":"YY Gent","year":"2012","unstructured":"Gent YY, Voskuyl AE, Kloet RW, et al. Macrophage positron emission tomography imaging as a biomarker for preclinical rheumatoid arthritis: findings of a prospective pilot study. Arthritis Rheum. 2012;64:62\u20136.","journal-title":"Arthritis Rheum"},{"key":"754_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/ard.2010.139527","volume":"70","author":"MG van de Sande","year":"2011","unstructured":"van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011;70:772\u20137.","journal-title":"Ann Rheum Dis"},{"key":"754_CR41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/art.37911","volume":"65","author":"L Barra","year":"2013","unstructured":"Barra L, Scinocca M, Saunders S, Bhayana R, Rohekar S, Racap\u00e9 M, et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum. 2013;65:1439\u201347.","journal-title":"Arthritis Rheum"},{"key":"754_CR42","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.34344","volume":"64","author":"MK Demoruelle","year":"2012","unstructured":"Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64:1756\u201361.","journal-title":"Arthritis Rheum"},{"key":"754_CR43","doi-asserted-by":"crossref","unstructured":"Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, Weisman MH, Norris JM, Holers VM, Deane KD Sputa autoantibodies in patients with established rheumatoid arthritis and subjects at-risk for future clinically apparent disease. Arthritis Rheum. 2013.","DOI":"10.1002\/art.38066"},{"key":"754_CR44","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1002\/art.34595","volume":"64","author":"TR Mikuls","year":"2012","unstructured":"Mikuls TR, Thiele GM, Deane KD, Payne JB, O'Dell JR, Yu F, et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum. 2012;64:3522\u201330.","journal-title":"Arthritis Rheum"},{"key":"754_CR45","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/art.34539","volume":"64","author":"JU Scher","year":"2012","unstructured":"Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012;64:3083\u201394.","journal-title":"Arthritis Rheum"},{"key":"754_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.0105-2896.2009.00850.x","volume":"233","author":"N Wegner","year":"2010","unstructured":"Wegner N, Lundberg K, Kinloch A, Fisher B, Malmstr\u00f6m V, Feldmann M, et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev. 2010;233:34\u201354.","journal-title":"Immunol Rev"},{"key":"754_CR47","doi-asserted-by":"crossref","unstructured":"Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2.","DOI":"10.7554\/eLife.01202"},{"key":"754_CR48","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/rheumatology\/kev347","volume":"55","author":"DM Gerlag","year":"2016","unstructured":"Gerlag DM, Norris JM, Tak PP. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology (Oxford). 2016;55:607\u201314.","journal-title":"Rheumatology (Oxford)"},{"key":"754_CR49","doi-asserted-by":"crossref","unstructured":"Sparks JA, Iversen MD, Yu Z, et al. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements:a randomized controlled trial. Arthritis Care Res (Hoboken). 2017.","DOI":"10.1002\/acr.23411"},{"key":"754_CR50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cct.2014.08.007","volume":"39","author":"JA Sparks","year":"2014","unstructured":"Sparks JA, Iversen MD, Miller Kroouze R, Mahmoud TG, Triedman NA, Kalia SS, et al. Personalized risk estimator for rheumatoid arthritis (PRE-RA) family study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. Contemp Clin Trials. 2014;39:145\u201357.","journal-title":"Contemp Clin Trials"},{"key":"754_CR51","unstructured":"SMILE (Study of Anti-Malarials in Incomplete Lupus). Cited 21-Mar-2018. at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03030118 ."}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-018-0754-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-018-0754-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:37:08Z","timestamp":1720363028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-018-0754-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,26]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s11926-018-0754-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.733520454.793547789","asserted-by":"object"}]},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,26]]},"assertion":[{"value":"26 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Deane reports grants from NIH, during the conduct of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"50"}}